

Highlights of This Issue 1219

SPOTLIGHT ON CLINICAL RESPONSE

- 1221 | **Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent**
Siqing Fu, Aung Naing, Caroline Fu, Macus Tien Kuo, and Razelle Kurzrock

REVIEW

- 1226 | **New Directions for Biologic Targets in Urothelial Carcinoma**
Suzanne Richter and Srikala S. Sridhar

THERAPEUTIC DISCOVERY

- 1236 | **Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer**
Neil E. Bhola, Maria L. Freilino, Sonali C. Joyce, Malabika Sen, Sufi M. Thomas, Anirban Sahu, Andre Cassell, Ching-Shih Chen, and Jennifer R. Grandis

- 1247 | **IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells**
Giusy Di Conza, Marianna Buttarelli, Olimpia Monti, Marsha Pellegrino, Francesca Mancini, Alfredo Pontecorvi, Katia Scotlandi, and Fabiola Moretti

- 1257 | **Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth**
Christine Helsen, Arnaud Marchand, Patrick Chaltin, Sebastian Munck, Arnout Voet, Annemieke Verstuyf, and Frank Claessens

- 1269 | **Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation**
William P. Katt, Sekar Ramachandran, Jon W. Erickson, and Richard A. Cerione

- 1279 | **An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 *trans*-Presentation at the Tumor Site**
Vanessa Kermer, Volker Baum, Nora Hornig, Roland E. Kontermann, and Dafne Müller

- 1289 | **STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression**
Shinji Kohsaka, Lei Wang, Kazuhiro Yachi, Roshan Mahabir, Takuhiro Narita, Tamio Itoh, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, and Shinya Tanaka

- 1300 | **Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions**
Rona Ortenberg, Yair Sapir, Lee Raz, Liat Hershkovitz, Ayelet Ben Arav, Sivan Sapoznik, Iris Barshack, Camila Avivi, Yackov Berkun, Michal J. Besser, Tehila Ben-Moshe, Jacob Schachter, and Gal Markel

- 1311 | **HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer**
Feng Su, Victor Grijalva, Kaveh Navab, Ekambaram Ganapathy, David Meriwether, Satoshi Imaizumi, Mohamad Navab, Alan M. Fogelman, Srinivasa T. Reddy, and Robin Farias-Eisner

- 1320 | **Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells**
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhao Liang, and Jiaoti Huang

PRECLINICAL DEVELOPMENT

- 1332 | **Proteasome Inhibition Blocks NF- κ B and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs**
Ali R. Jazirehi and James S. Economou

- 1342 | **Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications**
Juan Carlos Montero, Xi Chen, Alberto Ocaña, and Atanasio Pandiella

1353 | **The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models**

Yan Ning, Melissa J. Labonte, Wu Zhang, Pierre O. Bohanes, Armin Gerger, Dongyun Yang, Leonor Benhaim, David Paez, David O. Rosenberg, Kalyan C. Nagulapalli Venkata, Stan G. Louie, Nicos A. Petasis, Robert D. Ladner, and Heinz-Josef Lenz

1365 | **Effect of Small-Molecule-Binding Affinity on Tumor Uptake *In Vivo*: A Systematic Study Using a Pretargeted Bispecific Antibody**

Kelly Davis Orcutt, John J. Rhoden, Benjamin Ruiz-Yi, John V. Frangioni, and K. Dane Wittrup

1373 | **Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation**


Vlad C. Sandulache, Heath D. Skinner, Yuan Wang, Yunyun Chen, Cristina T. Dodge, Thomas J. Ow, James A. Bankson, Jeffrey N. Myers, and Stephen Y. Lai

CORRECTION

1381 | **Correction: Microtubule Inhibitors: Differentiating Tubulin-Inhibiting Agents Based on Mechanisms of Action, Clinical Activity, and Resistance**

ABOUT THE COVER

The CEACAM1 protein protects melanoma cells from cytotoxic lymphocytes *in vitro* via homophilic intercellular interactions. Immunohistochemistry of a human lymph node infiltrated with melanoma cells for CEACAM1 (brown pigmentation) and CD8 (pink pigmentation) showed that almost all CD8-positive lymphocytes in the tumor and its close vicinity were CEACAM1⁺, while most lymphocytes in other areas distant from tumor edge were mostly CEACAM1⁻. This strongly suggests that CEACAM1-mediated inhibition occurs *in vivo* and thus its blockade is a promising strategy for cancer immunotherapy. For details, see article by Ortenberg and colleagues on page 1300.



Molecular Cancer Therapeutics

11 (6)

Mol Cancer Ther 2012;11:1219-1381.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/11/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/11/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.